The Effect And Clinical Significance Of CD4⁺CD25^HighCD127^low Regularly T Cells In Patients With Rectal Cancer After Neoadjuvant Therapy

Objective:To explore the change of immune function and clinical significance in patients with rectal cancer after neoadjuvant therapy.Methods:Flow cytometry was used to analyze the proportions of Treg cells, CD4+T cells, CD8+T cells, NK cells, B cells, and CD4+/CD8+ratio in the peripheral blood from108patients with rectal cancer before and after neoadjuvant therapy. These patients were divided into down-staging group and not down-staging group according to the change of stage in accordance with TNM classification for rectal cancer after neoadjuvant therapy. Group t-test,analysis of variance and LSD-t test were used to study the changes after neoadjuvant therapy.Results:In the down-staging group, the proportions of Treg cells,B cells and the CD4+/CD8+ratio after neoadjuvant therapy were significantly lower than before neoadjunvat therapy (4.4±1.7%vs6.3±2.1%;3.4±3.2%vs8.9±4.0%;1.21±0.62vs1.51±0.51,all P<0.01). In the not down-staging group,the proportions of B cells and the CD4+/CD8+ratio after neoadjuvant therapy were significantly lower than before neoadjunvat therapy (3.0±1.9%vs8.5±2.1%;0.95±0.48vs1.48±0.68,both P<0.01).In addition,after neoadjunvat therapy, the proportions of Treg cells in the down-staging group were significantly lower than the not down-staging group (4.4±1.7%vs6.2±1.9%,P<0.05),while that CD4+/CD8+ratio was statistically higher(1.21±0.62vs0.95±0.48,p<0.05).The proportions of Treg cells in the group of TO, T1+T2and T3were increased in turn(3.5±1.5%vs4.8±1.7%vs5.7±1.6%,all p<0.05).The proportions of Treg cells in the NO group was significantly lower than N1group(3.1±1.4%vs5.5±1.6%,p<0.05).Conclusion:Patients in the down-staging group after neoadjuvant therapy,the proportion of Treg cells decreased, suggesting that Treg may be a valuable biomarker for assessing curative effect and prognosis.